Unaudited Financial results (Standalone and Consolidate) for the Quarter ended on 30 June 2026
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 06 Aug 2026, 10:31 PM IST · BSE ID: c8033c5d-5ab6-455b-9976-e5197c08bd22
View Original BSE Filing (PDF)
💡
In Simple Terms
Sai Life Sciences' Q1 FY27 profit increased, with standalone profit up 22.23% and consolidated profit up 17.58% year-on-year.
🤖 AI Summary
- Sai Life Sciences reported standalone profit of Rs. 713.39 million for Q1 FY27, a 22.23% increase from Q1 FY26.
- Standalone revenue from operations for the quarter ended June 30, 2026, was Rs. 5,467.29 million.
- Consolidated profit for the period reached Rs. 730.29 million, up 17.58% compared to Q1 FY26.
- Consolidated revenue from operations for Q1 FY27 stood at Rs. 5,542.85 million.
- The Board of Directors approved the unaudited standalone and consolidated financial results on August 06, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Standalone Revenue from operations (Q1 FY27)
5,467.29 million
13.19
Standalone Profit for the period (Q1 FY27)
713.39 million
22.23
Consolidated Revenue from operations (Q1 FY27)
5,542.85 million
11.66
Consolidated Profit for the period (Q1 FY27)
730.29 million
17.58
Standalone Basic EPS (Q1 FY27)
3.36
20.00
🏢 How This Affects the Company
The increase in revenue from operations for both standalone and consolidated entities indicates sustained business activity in contract research, development, and manufacturing services.
Higher profit for the period, both standalone and consolidated, directly impacts the company's earnings, reflecting improved financial performance compared to the prior year period.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected as the financial results provide an update on the company's performance, indicating changes in profitability and revenue.
🔍
Management Signal
The approval and disclosure of unaudited financial results signal management's adherence to regulatory compliance and transparent reporting of quarterly performance.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 results — assess if revenue growth trend continues.
Updates on new project wins or operational expansions.
Any further clarification on Labour Codes impact on liabilities.
LOW RISK
The filing indicates stable financial performance with no new significant risks.
💡 Investor Takeaway
Sai Life Sciences reported standalone profit of Rs. 713.39 million for Q1 FY27, marking a 22.23% year-on-year increase from Rs. 583.70 million. Consolidated profit also rose by 17.58% year-on-year to Rs. 730.29 million. Revenue from operations showed 13.19% standalone and 11.66% consolidated year-on-year growth.
⚖️ Strengths & Concerns
✅ Positives
- Standalone profit for the period increased by 22.23% year-on-year, reaching Rs. 713.39 million in Q1 FY27 from Rs. 583.70 million in Q1 FY26.
- Consolidated revenue from operations grew 11.66% year-on-year to Rs. 5,542.85 million in Q1 FY27 from Rs. 4,964.19 million in Q1 FY26.
⚠️ Concerns
- Standalone revenue from operations declined by 7.99% compared to the preceding quarter, falling from Rs. 5,943.40 million in Q4 FY26 to Rs. 5,467.29 million in Q1 FY27.
- Consolidated total income decreased by 9.68% quarter-on-quarter, from Rs. 6,176.58 million in Q4 FY26 to Rs. 5,578.28 million in Q1 FY27.
📅 Company Track Record
Sai Life Sciences' FY26 net profit surged 96.86% to Rs. 3,414.81 million, with revenue up 29% to Rs. 2,192 crore, as reported in May 2026. The Q1 FY27 results follow this growth, with standalone profit increasing 22.23% to Rs. 713.39 million.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Sai Life Sciences' standalone net profit for Q1 FY27?
Sai Life Sciences reported a standalone net profit of Rs. 713.39 million for the quarter ended June 30, 2026, marking a 22.23% increase from Rs. 583.70 million in Q1 FY26.
What was Sai Life Sciences' consolidated revenue from operations in Q1 FY27?
The consolidated revenue from operations for Sai Life Sciences in Q1 FY27 was Rs. 5,542.85 million, an 11.66% increase compared to Rs. 4,964.19 million in Q1 FY26.
How did Sai Life Sciences' standalone revenue perform year-on-year in Q1 FY27?
Standalone revenue from operations for Sai Life Sciences grew 13.19% year-on-year, from Rs. 4,830.38 million in Q1 FY26 to Rs. 5,467.29 million in Q1 FY27.
What was the consolidated profit for Sai Life Sciences in Q1 FY27?
The consolidated profit for the period for Sai Life Sciences in Q1 FY27 was Rs. 730.29 million, which is an increase of 17.58% from Rs. 621.10 million in Q1 FY26.
Questions based on this BSE filing only. For information purposes.